Toll Free: 1-888-928-9744

Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 31 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Pipeline Review, H1 2016', provides in depth analysis on Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) targeted pipeline therapeutics. 

The report provides comprehensive information on the Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7)
- The report reviews Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) Overview 6 Therapeutics Development 7 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Products under Development by Stage of Development 7 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Products under Development by Therapy Area 8 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Products under Development by Indication 9 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Pipeline Products Glance 10 Early Stage Products 10 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Products under Development by Companies 11 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Products under Development by Universities/Institutes 13 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Companies Involved in Therapeutics Development 20 ChemoCentryx, Inc. 20 Jyant Technologies, Inc. 21 Polyphor Ltd. 22 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Drug Profiles 23 CCX-650 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 CCX-771 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 JT-07 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Monoclonal Antibody for GBM and B-Cell Leukemia - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 POL-6926 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Atypical Chemokine Receptor 3 (Chemokine Orphan Receptor 1 or G-Protein Coupled Receptor 159 or G-Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7) - Dormant Projects 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 30 Disclaimer 31
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by ChemoCentryx, Inc., H1 2016 20 Pipeline by Jyant Technologies, Inc., H1 2016 21 Pipeline by Polyphor Ltd., H1 2016 22 Dormant Projects, H1 2016 29


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Actions, H1 2016 16 Number of Products by Molecule Types, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 18

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to

Read More...

Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commerc

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify